WO2005002417A2 - Genes lies au cancer utilises comme cible en chimiotherapie - Google Patents

Genes lies au cancer utilises comme cible en chimiotherapie Download PDF

Info

Publication number
WO2005002417A2
WO2005002417A2 PCT/US2004/019289 US2004019289W WO2005002417A2 WO 2005002417 A2 WO2005002417 A2 WO 2005002417A2 US 2004019289 W US2004019289 W US 2004019289W WO 2005002417 A2 WO2005002417 A2 WO 2005002417A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene
cell
expression
sequence
Prior art date
Application number
PCT/US2004/019289
Other languages
English (en)
Other versions
WO2005002417A3 (fr
Inventor
Bernd Weigle
Reinhard Ebner
Original Assignee
Avalon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Inc. filed Critical Avalon Pharmaceuticals, Inc.
Publication of WO2005002417A2 publication Critical patent/WO2005002417A2/fr
Publication of WO2005002417A3 publication Critical patent/WO2005002417A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des séquences de gènes liés au cancer, une séquence d'acides aminés dérivée, ainsi que des méthodes destinées au criblage d'agents antitumoraux potentiels sur la base de leur modulation de l'expression de ces gènes liés au cancer, et plus précisément de SOX11, exprimé dans les cancers du cerveau, du sein et du poumon. L'invention concerne également des anticorps réagissant auxdits polypeptides et des méthodes qui utilisent ces anticorps pour traiter divers troubles cancéreux et notamment pour cibler des cellules cancéreuses in vivo pour leur administrer des agents thérapeutiques. L'invention concerne également des méthodes permettant de diagnostiquer des cancers, qui utilisent ces séquences de gènes.
PCT/US2004/019289 2003-06-20 2004-06-17 Genes lies au cancer utilises comme cible en chimiotherapie WO2005002417A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48027503P 2003-06-20 2003-06-20
US60/480,275 2003-06-20

Publications (2)

Publication Number Publication Date
WO2005002417A2 true WO2005002417A2 (fr) 2005-01-13
WO2005002417A3 WO2005002417A3 (fr) 2006-03-30

Family

ID=33563811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019289 WO2005002417A2 (fr) 2003-06-20 2004-06-17 Genes lies au cancer utilises comme cible en chimiotherapie

Country Status (1)

Country Link
WO (1) WO2005002417A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008139169A1 (fr) 2007-05-11 2008-11-20 Immunovia Ab Expression de sox11 dans des lymphomes malins
WO2010023458A1 (fr) * 2008-09-01 2010-03-04 Immunovia Ab Procédé pour établir le diagnostic ou le pronostic d'un cancer épithélial de l'ovaire
WO2010146370A3 (fr) * 2009-06-19 2011-09-22 Immunovia Ab Agents et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086443A2 (fr) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086443A2 (fr) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [Online] AZUMA T ET AL: 'Human SOX11, an upregulated gene during the neural differentiation, has a long 3' untranslated region.', XP002994386 Retrieved from ncbi Database accession no. (AB028641) & DNA RES. vol. 6, no. 5, 1999, pages 357 - 560 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008139169A1 (fr) 2007-05-11 2008-11-20 Immunovia Ab Expression de sox11 dans des lymphomes malins
US9388469B2 (en) 2007-05-11 2016-07-12 Immunovia Ab Sox11 expression in malignant lymphomas
WO2010023458A1 (fr) * 2008-09-01 2010-03-04 Immunovia Ab Procédé pour établir le diagnostic ou le pronostic d'un cancer épithélial de l'ovaire
JP2012501318A (ja) * 2008-09-01 2012-01-19 イミュノヴィア・アーベー 上皮性卵巣癌の診断又は予後診断方法
WO2010146370A3 (fr) * 2009-06-19 2011-09-22 Immunovia Ab Agents et leurs utilisations
JP2012530120A (ja) * 2009-06-19 2012-11-29 イミュノヴィア・アーベー 薬剤およびその使用

Also Published As

Publication number Publication date
WO2005002417A3 (fr) 2006-03-30

Similar Documents

Publication Publication Date Title
US20060228705A1 (en) Cancer-linked gene as target for chemotherapy
US20050287147A1 (en) Cancer-linked gene as target for chemotherapy
US20050220798A1 (en) Cancer-linked gene as target for chemotherapy
WO2003105758A2 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
US20060099214A1 (en) Cancer-linked gene as target for chemotherapy
US20030219382A1 (en) Cancer-linked gene as target for chemotherapy
WO2003104401A2 (fr) Gene lie au cancer cible en chimiotherapie
WO2005002417A2 (fr) Genes lies au cancer utilises comme cible en chimiotherapie
US20060166212A1 (en) Breast specific protein expressed in cancer and methods of use thereof
CA2485981A1 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2005062788A2 (fr) Proteines specifiques de la prostate exprimees dans le cancer et methodes d'utilisation associees
WO2003076587A2 (fr) Genes lies au cancer utilises comme cibles ce chimiotherapie
WO2003104404A2 (fr) Gène lié au cancer servant de cible en chimiothérapie
WO2003105783A2 (fr) Gene associe au cancer servant de cible pour la chimiotherapie
CA2478607A1 (fr) Gene lie au cancer servant de cible pour la chimiotherapie
US20060110731A1 (en) Cancer-linked gene as target for chemotherapy
CA2478593A1 (fr) Genes lies au cancer utilises comme cibles en chimiotherapie
WO2003097801A2 (fr) Gene associe au cancer utilise comme cible pour une chimiotherapie
WO2003104419A2 (fr) Gene lie au cancer utilise en tant que cible pour la chimiotherapie
WO2003102164A2 (fr) Genes lies au cancer utilises comme cibles de chimiotherapie
WO2003104435A2 (fr) Genes lies au cancer servant de cibles de chimiotherapie
WO2003104436A2 (fr) Gène associé au cancer en tant que cible pour la chimiothérapie
WO2003097800A2 (fr) Gene associe au cancer utilise comme cible pour une chimiotherapie
WO2003106627A2 (fr) Gene lie au cancer gene utilise comme cible pour une chimiotherapie
WO2003106624A2 (fr) Gene lie au cancer utilise comme cible en chimiotherapie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase